Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

Lung Cancer ◽  
2020 ◽  
Vol 139 ◽  
pp. 22-27 ◽  
Author(s):  
Sai-Hong Ignatius Ou ◽  
Shirish M. Gadgeel ◽  
Fabrice Barlesi ◽  
James Chih-Hsin Yang ◽  
Luigi De Petris ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Safety Data ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pivotal Phase ◽  
Phase Ii Studies ◽  
Alk Positive

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9072-9072 ◽  
Author(s):  
Sai-Hong Ignatius Ou ◽  
Leena Gandhi ◽  
Shirish M. Gadgeel ◽  
Fabrice Barlesi ◽  
James Chih-Hsin Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Safety Data ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pivotal Phase ◽  
Phase Ii Studies ◽  
Alk Positive

scholarly journals Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (10) ◽  
pp. 1552-1560 ◽  
Author(s):  
James Chih-Hsin Yang ◽  
Sai-Hong Ignatius Ou ◽  
Luigi De Petris ◽  
Shirish Gadgeel ◽  
Leena Gandhi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Safety Data ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Pivotal Phase ◽  
Phase Ii Studies ◽  
Alk Positive

scholarly journals P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)

2017 ◽  
Vol 12 (1) ◽  
pp. S1170-S1171
Author(s):  
James Chih-Hsin Yang ◽  
Sai-Hong Ou ◽  
Luigi De Petris ◽  
Shirish Gadgeel ◽  
Leena Gandhi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Safety Data ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Two Phase ◽  
Phase Ii Studies

Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e20507-e20507 ◽  
Author(s):  
James Chih-Hsin Yang ◽  
Sai-Hong Ignatius Ou ◽  
Luigi De Petris ◽  
Shirish M. Gadgeel ◽  
Leena Gandhi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Pivotal Phase ◽  
Pooled Data ◽  
Phase Ii Studies

scholarly journals MA21.05 Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer

2019 ◽  
Vol 14 (10) ◽  
pp. S336
Author(s):  
S. Watanabe ◽  
N. Matsumoto ◽  
J. Koshio ◽  
A. Ishida ◽  
T. Tanaka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Trial ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

scholarly journals Results of a GlobaL Phase II Study with Crizotinib in Advanced ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

2012 ◽  
Vol 23 ◽  
pp. xi32-xi33
Author(s):  
D.-W. Kim ◽  
M.-J Ahn ◽  
Y. Shi ◽  
T.M. De Pas ◽  
P.-C Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive
Sign in / Sign up

Export Citation Format

Share Document